Methylation of O6-methylguanine-DNA methyltransferase (MGMT) has been extensively studied as a biomarker in predicting the prognosis of patients with GBM (Glioblastoma multiforme). Its significance has been studied in various subgroups, including age, gender and even race. Correlation between prognosis with MGMT methylation and different treatment regimens has also been studied in detail. There are multiple techniques to analyze MGMT methylation in tumour specimen. We review the current evidence for the importance of MGMT methylation as a biomarker for prognosis in GBM patients, the techniques to analyze it and the effect of epidemiologic factors on its significance.
JPMA. The Journal of the Pakistan Medical Association
(2018). The significance of MGMT methylation in glioblastoma multiforme prognosis. JPMA. The Journal of the Pakistan Medical Association, 68(7), 1137-1139.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_surg_neurosurg/157
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License